Study Title: A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age (CELIA)


The CELIA study is a phase 2, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of BIIB080 in patients with mild cognitive impairment or mild Alzheimer’s disease dementia. BIIB080 is an anti-sense oligonucleotide that prevents translation of the tau protein, a protein that is correlated with neuronal loss and cognitive decline. Participants would be assigned to one of 3 different doses or placebo intrathecally every 12 weeks.

Duration: 2 years, including a series of screening visits and safety follow-up.

Requirements to participate in the study include:

  • Age: 50-80 years old, inclusive
  • Have a diagnosis of MCI (mild cognitive impairment) or mild Alzheimer’s disease.
  • Consent to APOE genotyping.

(Principal Investigator: Maryam Beigi, MD, Easton Center’s Katherine and Benjamin Kagan Alzheimer’s Disease Treatment Development Program))

Contact: Lorena Macias at (310) 794-6191 or send an email to to participate in this study or for more information.

More information on the CELIA study is available at ID#: NCT05399888.

PDF Flyer